HYBRID EVENT: Join us in person in London, UK or attend virtually from anywhere.
Neonatal sarcomas represent an intricate subset of Paediatric cancers characterized by the aberrant proliferation of mesenchymal tissue in the first month of life. Within this unique category, a diverse array of histological subtypes manifests, encompassing rhabdomyosarcoma, fibrosarcoma, and malignant peripheral nerve sheath Tumours, among others. Neonatal sarcomas pose a formidable challenge in clinical management due to their rarity and the inherent complexities associated with early infancy, such as limited communication of symptoms, diagnostic difficulties, and distinctive biological behaviour. The etiological factors contributing to neonatal sarcomas remain elusive, with a multifactorial interplay involving genetic predispositions, prenatal exposures, and random mutational events. Clinical presentation varies widely, ranging from palpable masses to non-specific systemic symptoms, necessitating a high index of suspicion and a multidisciplinary diagnostic approach involving imaging studies, histopathological examinations, and molecular analyses. Treatment strategies hinge on a delicate balance between achieving oncological control and minimizing morbidity in this vulnerable population, often incorporating a multimodal approach combining surgery, chemotherapy, and radiation therapy. The intricate interplay between the immature physiology of neonates and the aggressive nature of sarcomas underscores the critical importance of tailored therapeutic interventions. As research endeavors strive to unravel the underlying molecular mechanisms and refine therapeutic modalities, neonatal sarcomas remain an area of poignant concern, demanding collaborative efforts to enhance early detection, optimize treatment outcomes, and ultimately improve the prognosis for these young patients.
